• 1
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. HEPATOLOGY 2006; 43: S99S112.
  • 2
    Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Non-alcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002; 35: 367372.
  • 3
    Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CDA, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis; May 6, 2006, epub ahead of print.
  • 4
    Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 35413546.
  • 5
    Targher G. Association between liver histology and early carotid atherosclerosis in patients with nonalcoholic fatty liver disease (Letter). HEPATOLOGY 2005; 42: 974975.
  • 6
    Owens D. The extended postprandial phase in diabetes. Biochem Soc Transact 2003; 31: 10851089.
  • 7
    Ravikumar B, Carey PE, Snaar JEM, Deelchand DK, Cook DB, Neely RDG, et al. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. Am J Physiol Endocrinol Metab 2005; 288: E789E797.
  • 8
    Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 13431351.
  • 9
    Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. HEPATOLOGY 2005; 42: 11751183.
  • 10
    Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic sttohepatitis. J Hepatol 2004; 40: 781786.
  • 11
    Karpe F, Lundahl B, Ehrenborg E, Eriksson P, Hamsten A. A common functional polymorhism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 1998; 18: 756761.
  • 12
    Lundahl B, Leren TP, Ose L, Hamsten A, Karpe F. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP –493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 17841788.
  • 13
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 316.
  • 14
    Prati D, Taioli E, Zanella A, Della Torre E, Budelli S, Del Vecchio E, et al. Updated definitions ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 19.
  • 15
    Nunez C, Gallagher D, Visser M, Pi-Sunyer FX, Wang Z, Heynsfield SB. Bioimpedance analysis: evaluation of leg-to-leg system based on pressare contact footpad electrodes. Med Sci Sports Exerc 1997; 29: 524531.
  • 16
    Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 14621470.
  • 17
    Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in Nonalcoholic Steatohepatitis. HEPATOLOGY 2003; 37: 909916.
  • 18
    Stocks SG, Miller NE. Capillary electrophoresis to monitor the oxidative modification of LDL. J Lipid Res 1998; 39: 13051309.
  • 19
    Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C. NHLBI/AHA Conference Proceedings. Definition of the metabolic syndrome. Circulation 2004; 109: 433438.
  • 20
    Swift LL, Kakkad B, Boone C, Jovanovska A, Gray Jerome W, Mohler PJ, et al. Microsomal triglyceride transfer protein expression in adipocytes: a new component in fat metabolism. FEBS Lett 2005; 579: 31833189.
  • 21
    Lu L, Zeng M, Li J, Hua J, Fan J, Fan Z, et al. Effects of Kupffer cells stimulated by triglyceride and very low-density lipoprotein on proliferation of rat hepatic stellate cells. Chin Med 1999; 112: 325329.
  • 22
    Ustundag Y, Ozer IO, Yenidunia S. Oxidized low density lipoprotein in liver tissue samples of our NASH patients, alcoholic and chronic viral hepatitis cases Gastroenterology 2002; 57: 203.
  • 23
    Ikura Y, Ohsaka M, Fukushima M, Ryo Y, Muraguchi T. Increased expression of the scavenger receptor CD36 in activated stellate cells in steatotic livers; its relation to fibrotic process in non-alcoholic fatty liver disease. HEPATOLOGY 2005; 42:S1: 620A
  • 24
    Pan M, Cederhaum AI, Zhang YL, Ginsberg HW, Williams KJ, Fisher FA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004; 113: 12771287.
  • 25
    Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2006 (in press).
  • 26
    Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effects of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003; 36: 421429.
  • 27
    Sposito AC, Gonbert S, Turpin G, Chapman MJ, Thillet J. Common polymorphism in the MTP promoter attenuates the dyslipidemic and proatherogenic effects of excess body weight. Arterioscler Thromb Vasc Biol 2004; 24: e143.
  • 28
    Koruk M, Savas C, Yilmaz O, Yaysi S, Karakok M, Gungdogdu C, et al. Serum Lipids, lipoproteins and apolipoproteins in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2003; 37: 177182.
  • 29
    Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved mtabolic control reduces the number of postprandial apolipoprotein B48-containing particles in type 2 diabetes. Atherosclerosis 2000; 148: 283291.
  • 30
    Phillips C, Bennett A, Anderton K, Owens D, Collins P, White D, et al. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metabolism 2002; 51: 847852
  • 31
    Phillips C, Bell M, Owens D, Collins P, Tomkin G. A common polymorphism of microsomal triglyceride transfer protein (-493 G/T) is associated with increased small chylomicron particles in diabetes. Atherosclerosis 2002; 3(Suppl 2): 185.
  • 32
    Phillips C, Mullan K, Owens D, Tomkin GH. Microsomal triglyceride transfer protein polymorphisms and lipoprotein levels in type 2 diabetes. Q J Med 2004; 97: 211218.
  • 33
    Watts GF, Riches FM, Humpries SE, Talmud PJ, vanBockxmeer FM. Genotypic association of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 2000; 41: 481488.
  • 34
    Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755765.
  • 35
    Schonfeld G, Patterson BW, Yablonskiy DA, Tavoli TSK, Averna M, Elias N, et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003; 44: 470478.
  • 36
    Martins IJ, Mortimer B-C, Miller J, Redgrave TG. Effects of particle size and number size on the plasma clearance of chylomicrons and remnants. J Lipid Res 1996; 37: 26962705.
  • 37
    Von Eynatten M, Schneider JG, Humpert PM, Rudofsky G, Schmidt N, Barosch P, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004; 27: 29252929.